Dr. Hill Discusses the Treatment Landscape of CLL

Brian T. Hill, MD, PhD
Published: Wednesday, Oct 31, 2018



Brian T. Hill, MD, PhD, assistant professor, Hematology and Oncology, Cleveland Clinic, discusses the treatment landscape of chronic lymphocytic leukemia (CLL).

Hill says that the treatment of CLL has drastically changed over the past 5 years. In contrast to the old way of treatment, which was chemotherapy or chemoimmunotherapy, there are many highly-active and effective agents for the treatment of CLL now. This can pose a challenge for general oncologists who need to select from these treatments and sequence them, Hill says.

Chemoimmunotherapy is still active and appropriate for some patients with CLL, but the Bruton tyrosine kinase inhibitors remain the go-to agents for relapsed disease and in the frontline for patients with 17p deletion or other molecular aberrations, Hill says. These patients who have molecular aberrations have historically done worse with chemotherapy, he adds.
SELECTED
LANGUAGE


Brian T. Hill, MD, PhD, assistant professor, Hematology and Oncology, Cleveland Clinic, discusses the treatment landscape of chronic lymphocytic leukemia (CLL).

Hill says that the treatment of CLL has drastically changed over the past 5 years. In contrast to the old way of treatment, which was chemotherapy or chemoimmunotherapy, there are many highly-active and effective agents for the treatment of CLL now. This can pose a challenge for general oncologists who need to select from these treatments and sequence them, Hill says.

Chemoimmunotherapy is still active and appropriate for some patients with CLL, but the Bruton tyrosine kinase inhibitors remain the go-to agents for relapsed disease and in the frontline for patients with 17p deletion or other molecular aberrations, Hill says. These patients who have molecular aberrations have historically done worse with chemotherapy, he adds.



View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: Addressing Post-Transplant Obstacles: Current and Emerging Strategies to Evolve the Standard of Care for Patients With Graft-Versus-Host DiseaseMar 28, 20192.0
2017 Year in Review™: Clinical Impact of Immunotherapies in the Treatment of CancerMar 30, 20191.75
Publication Bottom Border
Border Publication
x